NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)?Did you purchase your shares between March 10, 2024 and September 29, 2025, inc ...

Core Insights - Xilio Therapeutics, Inc. is set to present late-breaking data on vilastobart, a tumor-activated anti-CTLA-4 therapy, at the SITC 40th Annual Meeting from November 5-9, 2025 [1] - The Phase 2 data will focus on the response rate of vilastobart in combination with atezolizumab for patients with microsatellite stable metastatic colorectal cancer and high plasma tumor mutational burden [1] Presentation Details - The abstract title for the presentation is "Plasma Tumor Mutational Burden (pTMB) Enriched for Response to Vilastobart in Combination with Atezolizumab in Patients with Microsatellite Stable (MSS) Metastatic Colorectal Cancer" [2] - The late-breaking abstract number is 1315, and the presentation is scheduled for November 7, 2025, from 9:00 a.m. to 7:00 p.m. EST at the Gaylord National Resort and Convention Center [2] Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects [3] - The company utilizes a proprietary platform to advance a pipeline of novel tumor-activated immuno-oncology molecules designed to enhance therapeutic efficacy within the tumor microenvironment [3]

Core Insights - Xilio Therapeutics, Inc. announced a late-breaking poster presentation for vilastobart, a tumor-activated anti-CTLA-4 therapy, at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting [1] - The Phase 2 data will focus on the response rate of vilastobart in combination with atezolizumab for patients with microsatellite stable metastatic colorectal cancer and high plasma tumor mutational burden [1] Presentation Details - Abstract Title: Plasma Tumor Mutational Burden (pTMB) Enriched for Response to Vilastobart in Combination with Atezolizumab in Patients with Microsatellite Stable (MSS) Metastatic Colorectal Cancer [2] - Late-Breaking Abstract Number: 1315 [2] - Presentation Date: November 7, 2025 [2] - Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center [2] - The poster will be available on the Xilio Therapeutics website on the same day [2] Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects [3] - The company utilizes a proprietary platform to advance a pipeline of novel tumor-activated immuno-oncology molecules designed to enhance therapeutic efficacy within the tumor microenvironment [3]

Accessibility StatementSkip Navigation ENCINITAS, Calif. and WASHINGTON D.C., Oct. 30, 2025 /PRNewswire/ -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) and Global Genes today announced that Kiora has joined Global Genes' RARE-X Vision Consortium, a corporate-nonprofit partnership with a mission to promote and facilitate collaboration among advocacy, research, and industry stakeholders to advance research leading to vision-improving therapies. The Vision Consortium aims to transform the lives of people affect ...

Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials spanning all phasesBOSTON and LONDON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the formation of its Scientific Advisory Board (SAB) and inaugural appointment of Dr. Sara Hurvitz. “The formation of our SAB marks an important step ...

Reaching Patients Through Immunology Innovation 3Q 202 5 FINANCIAL RESULTS CALL OCTOBER 30, 202 5 1 Forward Looking Statements This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to ...

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its third quarter 2025 financial results and provide a business update on Friday, November 7th, 2025, before market open. The company will be hosting a teleconference in conjunction with this press release w ...

Third Quarter 2025 Financial Results Conference Call October 30, 2025 Forward-looking statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "projec ...

Third Quarter 2025 Financial Results October 30, 2025 © 2025 Alnylam Pharmaceuticals, Inc. 1 Agenda Welcome • Christine Akinc Chief Corporate Communications Officer Overview • Yvonne Greenstreet, M.D., MBA Chief Executive Officer Commercial Highlights • Tolga Tanguler Chief Commercial Officer Pipeline • Pushkal Garg, M.D. Chief Research & Development Officer Financial Summary and Upcoming Milestones • Jeff Poulton Chief Financial Officer Q&A Session 2 Alnylam Forward Looking Statements This presentation con ...

Accessibility StatementSkip Navigation Collaboration will leverage AI-powered neural analysis and Compass' expertise in psychedelic drug development to advance new therapies for mental health KEARNY, N.J., Oct. 30, 2025 /PRNewswire/ -- NeuroKaire, a pioneer in precision psychiatry and neurology, has launched an R&D collaboration with Compass Pathways, a leading biotechnology company dedicated to transforming mental health care. This collaboration aims to deepen the mechanistic understanding of psychedelic c ...